Proportion of participants with self‐rated clinically significant hair regrowth · women with FPHL
Finasteride showed no clear difference in the proportion of participants with self‐rated clinically… compared with placebo (low certainty).
1 finding from 1 review
Change in quality of life ‐ not measured · women with FPHL
1 finding from 1 review
Adverse events · women with FPHL
Finasteride showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants with investigator‐rated clinically significant hair regrowth · women with FPHL
Finasteride showed no clear difference in proportion of participants with investigator‐rated clinically… compared with placebo (low certainty).
1 finding from 1 review
Change from baseline to study conclusion in total hair count · women with FPHL
1 finding from 1 review
Degree of hair shedding from baseline to the end of the study · women with FPHL
1 finding from 1 review
Cosmetic appearance of the hair or participant satisfaction · women with FPHL
Finasteride showed no clear difference in cosmetic appearance of the hair or participant satisfaction compared with placebo (low certainty).
1 finding from 1 review
Change in quality (or pattern) of hair regrowth (e.g. thickness) ‐ not measured · women with FPHL
1 finding from 1 review
Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
1 finding from 1 review
Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · women with hirsutism
Finasteride 5 mg showed no clear difference in proportion of participants who reported an adverse event compared with spironolactone 100 mg (moderate certainty).
1 finding from 1 review
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism
1 finding from 1 review
Change in serum androgen levels · women with hirsutism
1 finding from 1 review
Change in BMI ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
Finasteride 5 mg showed no clear difference in participant‐reported improvement of hirsutism 4‐point Likert scale compared with flutamide 250 mg once to b.i.d. (low certainty).
1 finding from 1 review
Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · women with hirsutism
It is very uncertain whether finasteride 5 mg changes proportion of participants who reported an adverse event compared with flutamide 250 mg once to b.i.d. (very low certainty).
1 finding from 1 review
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism
1 finding from 1 review
Change in serum androgen levels · women with hirsutism
1 finding from 1 review